SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
CVM

Cel Sci Corp (New York Stock Exchange Arca:CVM)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.21-$0.26 (-17.69%)
 
Market cap
$21.3M
Insider Score
Health Score
Analyst consensus
Listed since
Dec 8, 1983
Market Cap$21.28M-80.7%
Revenue (ttm)$0
Net Income-$22.70M+10.7%
EPS-$2.58+74.2%
Shares Out17.59M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume879,700
Open$1.53
Previous Close$1.47
Day's Range$1.19 - $1.59
52-Week Range$0.89 - $7.80
Beta0.62
AnalystsBuy
Price Targetn/a
Earnings DateDec 23, 2026

About CVM

CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.

Address
8229 Boone Boulevard, Vienna, VA, 22182, US
Market Cap
21 million
Employees
43
Industrial Classification
Biotechnology

Cel Sci Corp Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
0th Percentile Overall Score
CVM InsiderScore:26 / 99

Cel Sci Corp scored higher than 0% of companies evaluated by InsiderBuying, and ranked 101st out of 102 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Cel Sci Corp bought $138.0K of stock across 1 purchase in the last 90 days, the largest of them $138.0K.

Stake Increase

The average purchase added about 46% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$867.00K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From CVM’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-17.69%
5 Days
-8.33%
1 Month
-25.31%
6 Months
-16.55%
1 Year
-80.67%

$CVM stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in CVM holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by CVM's directors and management

Net Shares Purchased by Insiders−400k−200k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

CVM Estimated quarterly lobbying spending

Source: U.S. Senate LDA

CVM Revenue by Segment

$2.16MTotal
Stock-based compensation$1.35M62.42%
Public & investor relation costs$333.00K15.41%
Legal & accounting fees$287.00K13.28%
Supplies & materials$192.00K8.89%

As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New CVM patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to CVM from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in CVM

VTIVanguard Morningstar Total Stock Market ETF$496.91K
VXFVanguard Extended Market ETF$154.12K
SILXETFMG Prime 2x Daily Junior Silver Miners ETF$33.48K
VALTETFMG Sit Ultra Short ETF$17.80K
GERMETFMG Treatments, Testing and Advancements ETF$14.65K
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF$10.00K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from CVM’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
21.67
Analyst Ratings
40% of score
60
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
5
Sells
0
Buy Value
$867.00K
Distinct Buyers
1

Insider Score Trend Over Time

+8.5 since Sep 23
0255075100Sep 23 — Insider Score 13.2Sep 24 — Insider Score 12.5Sep 25 — Insider Score 36.0Sep 26 — Insider Score 35.6Sep 27 — Insider Score 35.8Sep 28 — Insider Score 35.7Sep 29 — Insider Score 35.1Sep 30 — Insider Score 35.0Oct 1 — Insider Score 34.1Oct 2 — Insider Score 40.0Oct 3 — Insider Score 33.8Oct 4 — Insider Score 34.1Oct 5 — Insider Score 34.2Oct 6 — Insider Score 33.4Oct 7 — Insider Score 32.9Oct 8 — Insider Score 32.7Oct 9 — Insider Score 32.6Oct 10 — Insider Score 32.1Oct 11 — Insider Score 33.2Oct 12 — Insider Score 33.3Oct 13 — Insider Score 33.1Oct 14 — Insider Score 32.9Oct 15 — Insider Score 32.9Oct 16 — Insider Score 32.6Oct 17 — Insider Score 32.5Oct 18 — Insider Score 32.9Oct 19 — Insider Score 32.6Oct 20 — Insider Score 32.7Oct 21 — Insider Score 32.6Oct 22 — Insider Score 32.7Oct 23 — Insider Score 32.5Oct 24 — Insider Score 32.5Oct 25 — Insider Score 32.1Oct 26 — Insider Score 32.1Oct 27 — Insider Score 32.3Oct 28 — Insider Score 32.2Oct 29 — Insider Score 32.3Oct 30 — Insider Score 31.3Oct 31 — Insider Score 30.9Nov 1 — Insider Score 31.3Nov 2 — Insider Score 31.4Nov 3 — Insider Score 30.8Nov 4 — Insider Score 30.7Nov 5 — Insider Score 30.1Nov 6 — Insider Score 29.5Nov 7 — Insider Score 28.9Nov 8 — Insider Score 29.9Nov 9 — Insider Score 29.3Nov 10 — Insider Score 28.2Nov 11 — Insider Score 27.4Nov 12 — Insider Score 28.2Nov 13 — Insider Score 27.2Nov 14 — Insider Score 26.3Nov 15 — Insider Score 26.9Nov 16 — Insider Score 26.8Nov 17 — Insider Score 25.6Nov 18 — Insider Score 24.7Nov 19 — Insider Score 23.7Nov 20 — Insider Score 22.3Nov 21 — Insider Score 21.7Sep 23Oct 22Nov 21

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

GERMETFMG Treatments, Testing and Advancements ETF0.16%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.01%

Weight is the stock’s share of each fund’s holdings.